US · DVA
DaVita Inc.
- Sector
- Healthcare · Medical - Care Facilities
- Headquarters
- Denver, CO 80202
- Website
- davita.com
Price · as of 2025-12-31
$151.65
Market cap 10.45B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $150.89 | -0.5% |
| Intrinsic Value(DCF) | $61.62 | -59.37% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $123.62 | -18.48% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $43.11 | $64.92 | $65.64 | $0.00 | $33.57 |
| 2012 | $59.36 | $97.56 | $6.16 | $0.00 | $77.69 |
| 2013 | $68.78 | $98.10 | $545.16 | $0.00 | $150.94 |
| 2014 | $80.81 | $97.60 | $437.67 | $0.00 | $56.36 |
| 2015 | $71.05 | $85.17 | $221.57 | $0.00 | $19.85 |
| 2016 | $68.55 | $96.52 | $5.37 | $0.00 | $64.69 |
| 2017 | $72.46 | $84.39 | $1.09 | $7.41 | $0.00 |
| 2018 | $49.95 | $59.48 | $0.00 | $0.00 | $11.87 |
| 2019 | $81.84 | $85.09 | $0.00 | $0.00 | $42.03 |
| 2020 | $108.44 | $89.53 | $0.00 | $0.00 | $61.15 |
| 2021 | $109.97 | $92.44 | $0.00 | $0.00 | $80.94 |
| 2022 | $74.68 | $73.73 | $0.00 | $0.00 | $49.00 |
| 2023 | $135.17 | $100.31 | $0.00 | $0.00 | $95.44 |
| 2024 | $147.02 | $133.86 | $1.75 | $0.00 | $148.59 |
| 2025 | $153.98 | $150.89 | $0.00 | $0.00 | $123.62 |
AI valuation
Our deep-learning model estimates DaVita Inc.'s (DVA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $150.89
- Current price
- $151.65
- AI upside
- -0.5%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$61.62
-59.37% upside
Graham-Dodd
—
— upside
Graham Formula
$123.62
-18.48% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| DVA | DaVita Inc. | $151.65 | 10.45B | -1% | -59% | — | -18% | 12.29 | -20.36 | 0.97 | 10.42 | — | -1.57 | 27.00% | 14.74% | 5.47% | -407.09% | 12.61% | 6.21% | -23.12 | 3.66 | 1.29 | 1.19 | 5.41 | -1137.00% | 646.00% | -1063.00% | 9.89% | 0.60 | 10.50% | 0.00% | 0.00% | 13.52% | 13.69 | 21.00 | 2.02 | 1.68 |
| ALGN | Align Technology, Inc. | $190.10 | 13.64B | +1% | -52% | -59% | -74% | 33.42 | 3.39 | 3.40 | 15.94 | 6259.75 | 3.96 | 68.33% | 15.27% | 10.17% | 10.39% | 14.49% | 6.59% | 0.02 | — | 1.36 | 1.14 | -1.27 | 53.00% | 90.00% | -473.00% | 4.33% | 0.31 | 19.89% | 0.00% | 0.00% | 0.64% | 20.61 | 21.41 | 3.15 | 4.87 |
| ATR | AptarGroup, Inc. | $143.71 | 9.43B | -31% | -59% | -82% | -45% | 23.88 | 3.52 | 2.48 | 12.63 | 366.80 | 7.03 | 29.58% | 13.53% | 10.40% | 15.28% | 11.48% | 8.11% | 0.57 | 9.69 | 1.62 | 1.04 | 1.36 | 651.00% | 542.00% | -1422.00% | 3.19% | 0.49 | 8.43% | 1.29% | 30.80% | 5.18% | 20.55 | 35.05 | 2.78 | 4.13 |
| BIO | Bio-Rad Laboratories, Inc… | $278.44 | 7.52B | +7% | -54% | +41% | -13% | 10.03 | 1.02 | 2.95 | 15.99 | — | 1.14 | 52.01% | 10.47% | 29.42% | 10.84% | 3.01% | 7.62% | 0.21 | 5.52 | 5.62 | 3.90 | 2.10 | -14264.00% | 65.00% | 4072.00% | 4.91% | 1.03 | 5.46% | 0.00% | 0.00% | 3.88% | 28.14 | 20.32 | 2.95 | 3.15 |
| BMRN | BioMarin Pharmaceutical I… | $61.73 | 11.86B | +37% | -52% | -36% | -40% | 32.84 | 1.88 | 3.56 | 18.32 | — | 2.02 | 77.13% | 16.56% | 10.83% | 5.94% | 7.50% | 4.79% | 0.10 | 48.95 | 5.21 | 3.25 | -1.25 | -1855.00% | 1287.00% | 5249.00% | 6.33% | 1.09 | 14.09% | 0.00% | 0.00% | 3.68% | 19.67 | 14.48 | 3.26 | 5.75 |
| CHE | Chemed Corporation | $410.01 | 5.97B | -25% | -56% | -80% | -46% | 22.87 | 6.19 | 2.40 | 14.53 | — | 26.42 | 29.97% | 13.37% | 10.48% | 25.28% | 23.68% | 16.54% | 0.15 | 193.28 | 1.05 | 0.90 | 0.16 | -739.00% | 406.00% | -1155.00% | 5.36% | 1.35 | 30.56% | 0.52% | 11.90% | 7.63% | 18.14 | 18.85 | 2.43 | 9.79 |
| ENSG | The Ensign Group, Inc. | $214.17 | 12.45B | -38% | +33% | -70% | -27% | 35.93 | 5.54 | 2.45 | 28.09 | 255.48 | 5.81 | 13.74% | 8.58% | 6.80% | 16.92% | 7.20% | 6.80% | 1.86 | 54.31 | 1.42 | 1.35 | 6.43 | 1406.00% | 1872.00% | 9620.00% | 3.00% | 0.63 | 8.15% | 0.12% | 4.20% | 0.29% | 36.77 | 43.03 | 3.15 | 4.02 |
| HSIC | Henry Schein, Inc. | $82.39 | 9.99B | +2% | -60% | -90% | -52% | 24.70 | 3.03 | 0.75 | 13.28 | 342.43 | -4.95 | 29.14% | 5.75% | 3.02% | 11.99% | 9.02% | 3.71% | 1.14 | 5.05 | 1.38 | 0.56 | 3.51 | 721.00% | 403.00% | -1331.00% | 5.83% | 0.22 | 8.87% | 0.00% | 0.00% | 8.65% | 17.63 | 23.32 | 1.01 | 2.86 |
| MOH | Molina Healthcare, Inc. | $154.05 | 7.93B | +43% | +423% | -46% | +17% | 16.40 | 1.90 | 0.17 | 7.63 | — | 4.13 | 8.97% | 1.72% | 1.04% | 11.02% | 52.20% | 3.03% | 0.97 | 4.07 | 1.69 | 1.06 | -0.31 | -5632.00% | 1175.00% | -21691.00% | -8.21% | -0.07 | -53.04% | 0.00% | 0.00% | 12.92% | 9.53 | -11.70 | 0.16 | 4.20 |
| RVMD | Revolution Medicines, Inc… | $102.02 | 19.72B | — | — | — | — | -17.08 | 11.84 | — | -16.01 | -25.80 | 12.38 | 0.00% | — | — | -58.07% | 1908.09% | -46.06% | 0.10 | -48.80 | 7.14 | 6.97 | 0.21 | 6620.00% | — | 6094.00% | -4.73% | -3.09 | 1474.57% | 0.00% | 0.00% | 0.00% | -14.76 | -19.10 | — | 13.58 |
| UHS | Universal Health Services… | $206.10 | 13.12B | -29% | -58% | -24% | +99% | 8.68 | 1.80 | 0.76 | 6.73 | 23.26 | 3.99 | 11.48% | 11.48% | 8.57% | 21.68% | 12.66% | 10.08% | 0.76 | 12.68 | 1.05 | 0.85 | 1.95 | 3734.00% | 971.00% | -2440.00% | 6.47% | 0.58 | 7.04% | 0.39% | 3.40% | 7.77% | 9.27 | 21.78 | 1.07 | 3.24 |
About DaVita Inc.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services to 16,000 patients in risk-based integrated care arrangements and 7,000 patients in other integrated care arrangements; vascular access services; clinical research programs; physician services; and comprehensive kidney care services. As of December 31, 2021, it provided dialysis and administrative services in the United States through a network of 2,815 outpatient dialysis centers serving approximately 203,100 patients; and operated 339 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 39,900 patients. Further, the company provides acute inpatient dialysis services in approximately 850 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
- CEO
- Javier J. Rodriguez
- Employees
- 76K
- Beta
- 1.01
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($61.62 ÷ $151.65) − 1 = -59.37% (DCF, example).